Helios Clinical Research

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer2 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 1/22 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• BeiGene1 trial
• BeOne Medicines1 trial
• Bristol-Myers Squibb1 trial
• DualityBio Inc.1 trial

Running trials

• Recruiting

  A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

  NCT07554521· Phase 2· BeOne Medicines· Source

  Contact: Study Director

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Omkar Marathe, Site 0328

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

  NCT05609370· Phase 1/2· BeiGene· Source

• Recruiting

  A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

  NCT05150691· Phase 1/2· DualityBio Inc.· Source

  Contact: Britney Winterberger

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer1 recruiting
• Triple-negative breast cancer1 recruiting